TIMELY RHEUMATOID ARTHRITIS CONTROL WITH BIOLOGIC OR TARGETED SYNTHETIC DMARDS IN CLINICAL PRACTICE: SEPARATING SUCCESSES FROM OPPORTUNITIES FOR CARE IMPROVEMENT

被引：0
|
作者：
Helfgott, S. M. [1 ]
Huston, K. [2 ]
Singh, J. A. [2 ]
Frick, A. [3 ]
Milligan, S. [4 ]
Persons, D. [3 ]
Soloman, N. [5 ]
机构：
[1] Harvard Med Sch, Boston, MA USA
[2] Ctr Rheumat Dis & Allergy Immunol, Kansas City, MO USA
[3] Trio Hlth Analyt, Louisville, CO USA
[4] Trio Hlth Analyt, Belfast, ME USA
[5] Arizona Arthrit, Phoenix, AZ USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO54
引用
收藏
页码：S26 / S26
页数：1
相关论文
共 50 条
  • [1] Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry
    Lin, Ching-Tsai
    Huang, Wen-Nan
    Tsai, Wen-Chan
    Chen, Jun-Peng
    Hung, Wei-Ting
    Hsieh, Tsu-Yi
    Chen, Hsin-Hua
    Hsieh, Chia-Wei
    Lai, Kuo-Lung
    Tang, Kuo-Tung
    Tseng, Chih-Wei
    Chen, Der-Yuan
    Chen, Yi-Hsin
    Chen, Yi-Ming
    [J]. PLOS ONE, 2021, 16 (04):
  • [2] COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
    Tsai, Jih-Jin
    Liu, Li-Teh
    Chen, Chun-Hong
    Chen, Liang-Jen
    Wang, Shiow-Ing
    Wei, James Cheng-Chung
    [J]. RMD OPEN, 2023, 9 (03):
  • [3] THE VALUE OF TIMELY BIOLOGIC OR TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS THERAPY IN THE DEVELOPMENT OF OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE
    Matianova, E. V.
    Gordeev, A. V.
    Galushko, E. A.
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S379 - S379
  • [4] Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs
    Park, Sang Hee
    Schwartz, Taylor
    Han, Xue
    Robinson, Scott
    Kakehi, Sumie
    Wittstock, Keith
    Norris, Kris
    Murunga, Anne
    Silverstein, Alison
    Sparks, Jeffrey
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 957 - 958
  • [5] Treatment Patterns of Biologic/Targeted Synthetic DMARDs for the Management of Rheumatoid Arthritis in Australia: An Analysis of the OPAL Dataset
    Cooley, Helen
    Smith, Tegan
    Youssef, Peter
    Tymms, Kathleen
    Mathers, David
    Ciciriello, Sabina
    Griffiths, Hedley
    OSullivan, Catherine
    Littlejohn, Geoffrey
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [6] Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs
    Kalweit, Maria
    Burden, Andrea. M. H.
    Boedecker, Joschka
    Hugle, Thomas H.
    Burkard, Theresa
    [J]. PLOS COMPUTATIONAL BIOLOGY, 2023, 19 (06)
  • [7] Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry
    Gabay, Cem
    Riek, Myriam
    Scherer, Almut
    Finckh, Axel
    [J]. RHEUMATOLOGY, 2015, 54 (09) : 1664 - 1672
  • [8] SUITABILITY OF A NETWORK META-ANALYSIS OF TARGETED SYNTHETIC OR BIOLOGIC THERAPY FOR PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE BIOLOGIC DMARDS
    Peterson, S.
    Alfonso-Cristancho, R.
    Pacou, M.
    Belhadi, D.
    Van Sanden, s
    Webb, T.
    Ganguly, R.
    Kurrasch, R.
    Rao, R.
    Hsu, B.
    Popik, S.
    Jansen, J. P.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A141 - A141
  • [9] NEW BIOLOGIC AND TARGETED SYNTHETIC DMARDS FOR THE TREATMENT OF PSA. HOW ARE THEY POSITIONED IN CLINICAL PRACTICE?
    Martins, P.
    Nero, P.
    Lopes, Pestana J.
    Silva, I.
    Teixeira, R. L.
    Fonseca, J. E.
    Santos, M. J.
    Vieira-Sousa, Elsa
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : 1216 - 1217
  • [10] Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
    Pang, Mengduan
    Sun, Zhe
    Zhang, Hongfeng
    [J]. MEDICINE, 2022, 101 (32)
12345